The one-year clinical results from the TaurusTrio ALTER-AR study demonstrated a technical success rate of 99.1%, with 0% all-cause mortality at 30 days and only 2.6% at one year. Patients showed significant cardiac function improvement, with 91.7% recovering to NYHA class I/II at six months. The incidence of moderate or greater paravalvular leak was 0% at one year, and indicators such as LVEDV and LVM showed significant reverse remodeling, validating the device's long-term safety and efficacy. "Historically ...